BCL2 and lymphoma: Ezh2Y641F Bcl2+ chimeric mice led to early lymphoma development in 70% of mice at 111 days (vs 20% in mice overexpressing Ezh2WTBcl2+ and none in the Bcl2 control at that stage), characterized by enlarged spleen and liver and resembling morphologically to DLBCL with centroblastic morphology (73, 74).